Johnson & Johnson (JNJ) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divest...
Johnson & Johnson's revenue increased 6.0% year over year, from $88.82B to $94.19B.
Net income increased 90.6% over the same period, from $14.07B to $26.80B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 31% in total.
Total debt increased by 30.8% to $47.93B.
The debt-to-equity ratio stands at 0.59, indicating a moderate leverage profile.
Operating cash flow grew 1.1% to $24.53B.
Johnson & Johnson maintains a strong net profit margin of 28.5%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $22.47B+0.1% | $2.69B | $15.50B | $-25.0M | $7.99B | $178.29B | $35.75B | $70.16B |
| Q4 FY2024 | $22.52B+0.2% | $3.43B | $15.39B | $3.89B | $6.98B | $180.10B | $36.63B | $71.49B |
| Q1 FY2025 | $21.89B-2.8% | $11.00B | $14.54B | $6.34B | $4.17B | $193.67B | $52.25B | $78.11B |
| Q2 FY2025 | $23.74B+8.5% | $5.54B | $16.11B | $6.86B | $3.88B | $193.39B | $50.76B | $78.47B |
| Q3 FY2025 | $23.99B+1.1% | $5.15B | $16.69B | $14.41B | $9.17B | $192.82B | $45.80B | $79.28B |
| Q4 FY2025 | $24.56B+2.4% | $5.12B | $16.60B | $4.97B | $7.31B | $199.21B | $47.93B | $81.54B |
| Q1 FY2026 | $24.06B-2.0% | $5.24B | $15.96B | $5.99B | $2.51B | N/A | N/A | N/A |
| Q2 FY2026 | $25.31B+5.2% | $5.53B | $17.26B | $7.99B | $8.62B | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Johnson & Johnson (JNJ) Financial Statements & Revenue History
Johnson & Johnson (JNJ) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry trading at $255.00 with a market capitalization of $615. This page provides 42 historical financial statements for Johnson & Johnson, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Johnson & Johnson reported revenue of $94.2 billion, representing 6.0% year-over-year growth. The net profit margin of 28.5% reflects strong profitability. The debt-to-equity ratio of 0.59 reflects moderate leverage.
JNJ Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Johnson & Johnson's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether JNJ is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track JNJ's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Johnson & Johnson converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of JNJ's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use JNJ Financial Data
Investors use Johnson & Johnson's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare JNJ's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how JNJ's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View JNJ's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Johnson & Johnson's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.JNJ trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.